Sarepta Therapeutics(US:SRPT) Prnewswireยท2025-08-25 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its gene therapy product, ELEVIDYS, which poses significant safety risks to patients [1]. Group 1: Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics failed to disclose significant safety risks associated with ELEVIDYS, a prescription gene therapy for Duchenne [1]. - It is claimed that the trial regimes and protocols for ELEVIDYS did not adequately detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [1]. - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's safety and approval prospects [1]. Group 2: Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action, with a deadline set for August 25, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - There is no cost or obligation for shareholders to participate in this class action [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].